Subcutaneous Nivolumab Reduces Burden of Melanoma Care, Expert Says
Source: Oncology News Central, March 2025
In December, the U.S. Food and Drug Administration (FDA) approved nivolumab and hyaluronidase-nvhv (Opdivo Qvantig) for subcutaneous injection across all of nivolumab’s approved adult solid tumor indications, including melanoma.
Nivolumab is currently approved as a monotherapy for advanced melanoma, in combination with ipilimumab (Yervoy) for unresectable or metastatic melanoma across BRAF status, as an adjuvant monotherapy for resected melanoma with lymph node involvement, and as adjuvant monotherapy for resected stage IIB or IIC melanoma.
However, the new approval is only for indications as monotherapy, monotherapy maintenance after completion of ipilimumab combination therapy, or in combination with chemotherapy or cabozantinib (Cabometyx).